nr  | titel | auteur | datum |
|---|
| 6.07.4.60/47 | Nuclear Medicine's Double Hazard. Imperiled Treatment and the Risk of Terrorism | C.Hansell | juli 2008 |
| 6.07.4.60/46 | European Research Reactor Position Paper. Scenario for sustainable Molybdenum-99 production in Europe | CEA, NCBJ, NRG, PALLAS, RCR, SCK•CEN, TUM | juni 2018 |
| 6.07.4.60/45 | Emissions from Fission-Based Medical Isotope Production and their Effects on the International Monitoring System | Th.W.Bowyer | mei 2015 |
| 6.07.4.60/44 | Maximum reasonable radioxenon releases from medical isotope production facilities and their effect on monitoring nuclear explosions | Th.W.Bowyer, R.kephart, P.W.Eslinger, J.Friese | september 2012 |
| 6.07.4.60/43 | Isotopic noble gas signatures released from medical isotope production facilities- Simulations and measurements | P.Saey, Th.W.Bowyer, A.Ringbom | april 2010 |
| 6.07.4.60/42 | Marktontwikkeling en leveringszekerheid
voor medische radionucliden, aanvulling | Roobol, de Waard, RIVM | september 2019 |
| 6.07.4.60/41 | Marktontwikkeling en leveringszekerheid voor medische radionucliden
| Roobol, de Waard, RIVM | juli 2019 |
| 6.07.4.60/40 | Medical isotope production using Lighthouse accelerator | J.W.Blokker | november 2017 |
| 6.07.4.60/39 | Production Of 99Tc On A Medical Cyclotron: A Feasibility Study | J.E.Beaver. H.B.Hupf | november 1971 |
| 6.07.4.60/38 | Marktontwikkeling en leveringszekerheid voor medische isotopen | Roobol, de Waard, RIVM | april 2018 |
| 6.07.4.60/37 | Medical isotopes. Global importance and opportunities for the Netherlands in a European context
| Nucleair Nederland | november 2017 |
| 6.07.4.60/36 | 2016 Medical Isotope Supply Review | NEA | juni 2016 |
| 6.07.4.60/35 | Alternatives for the production of medical isotopes | Greenpeace Netherlands, Profundo, J.W.van Gelder, A.Herder | maart 2010 |
| 6.07.4.60/34 | Radio-activiteit in dienst van de arts | AO-reeks, T.van Leeuwen | november 1976 |
| 6.07.4.60/33 | Medische isotopen. Belang voor de wereld en kansen voor Nederland | Nucleair Nederland | april 2017 |
| 6.07.4.60/32 | Feasibility of Producing Molybdenum-99 on a Small Scale Using Fission of Low Enriched Uranium or Neutron Activation of Natural Molybdenum | IAEA | januari 2015 |
| 6.07.4.60/31 | Cyclotron Based Production of Technetium-99m | IAEA | juni 2017 |
| 6.07.4.60/30 | Productie en gebruik van medische radio-isotopen
in Nederland - Huidige situatie en toekomstverkenning | RIVM, Roobol, van der Reijden, de Waard–Schalk, Bijwaard | juli 2017 |
| 6.07.4.60/29 | 2017 Medical Isotope Supply Review: Mo/Tc Market Demand and Production Capacity Projection 2017-2022 | OECD, NEA | april 2017 |
| 6.07.4.60/28 | Ruwe schets van de problemen voor de behandeling van Nederlandse patiënten bij een plotselinge productiestop van medische isotopen in Nederland | RIVM, Smetsers, Bijwaard, Roobol | juli 2016 |
| 6.07.4.60/27 | Molybdenum-99 for Medical Imaging | National Academies of Sciences | september 2016 |
| 6.07.4.60/26 | Co-production of medical radioisotopes in the proposed Accelerator Production of Tritium Facility | LANL | december 1998 |
| 6.07.4.60/25 | Future Supply of Medical Radioisotopes for the UK Report 2014 | British Nuclear Medicine Society, Science & Technology Facilities Council | november 2014 |
| 6.07.4.60/24 | Nuclear Medicine without Nuclear Reactors or Uranium Enrichment | AAAS, Updegraff, Hoedl | mei 2013 |
| 6.07.4.60/23 | The Supply of Medical Radioisotopes. Implementation of the HLG-MR Policy Approach. Results from a Self-assessment by the Global 99Mo/99mTc Supply Chain | OECD, NEA | maart 2013 |
| 6.07.4.60/22 | Straling in ziekenhuizen | AbvaKabo | |
| 6.07.4.60/21 | Working materials Consultancy on Conversion planning for Mo-99 Production facilities from HEU to LEU | IAEA | augustus 2010 |
| 6.07.4.60/20 | Radioisotopes and life processes | W.Kosieleski, R.Baserga | 1967 |
| 6.07.4.60/19 | Radioisotopes in Medicine | E.W.Phelan, AEC | 1966 |
| 6.07.4.60/18 | Report on Molybdenum 99 production for nuclear medicine 2010-2020 | AIPES | november 2008 |